Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Unknown × Muscle Invasive Bladder Cancer × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 63 Breast Neoplasms 58 Neoplasms 53 Leukemia, Myeloid, Acute 53 Multiple Myeloma 46 Lymphoma 43 Stomach Neoplasms 41 Colorectal Neoplasms 41 Carcinoma, Hepatocellular 40 Recurrence 39 Neoplasm Metastasis 37 Pancreatic Neoplasms 36 Melanoma 34 Prostatic Neoplasms 31 Leukemia 29 Ovarian Neoplasms 24 Lymphoma, Non-Hodgkin 24 Lung Neoplasms 22 Glioblastoma 22 Lymphoma, Large B-Cell, Diffuse 21 Lymphoma, B-Cell 21 Esophageal Neoplasms 20 Precursor Cell Lymphoblastic Leukemia-Lymphoma 19 Hematologic Neoplasms 19 Myelodysplastic Syndromes 18 Leukemia, Lymphocytic, Chronic, B-Cell 18 Colonic Neoplasms 18 Lymphoma, Mantle-Cell 17 Carcinoma, Renal Cell 16 Squamous Cell Carcinoma of Head and Neck 15

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04813107 2022-02-22

ANTICIPATE

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 1/2 Unknown

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡